腾盛博药 - 突破创新洞察

标题

疾病领域
Safety, Tolerability, and Pharmacokinetics of BRII-732, A Medoxomil Carbonate Prodrug of Islatravir in Healthy Adult Subjects
Presentation at ID Week 2022

2022年10月21日

HIV
Safety, Tolerability, and Pharmacokinetics of BRII-778, A Modified-Release Oral Formulation of Rilpivirine in Healthy Adult Subjects
Presentation at ID Week 2022

2022年10月21日

HIV
Safety, Tolerability, and Pharmacokinetics of BRII-296, An Extended-Release Injectable Aqueous Suspension Formulation of Brexanolone in Healthy Adult Subjects
Presentation at the International Marcé Society Conference

2022年09月19日

PPD
Amubarvimab/Romlusevimab: First Approval
Drugs

2022年08月23日
Safety and Antiviral Activity of Two Monthly Administration of BRII-835 (VIR-2218), an X-Targeting RNAi Therapeutic, in Chinese Patients with Chronic HBV Infection
Presentation at the 2022 APASL conference

2022年03月31日

乙型肝炎
Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study
JHEP Reports

2021年09月07日

乙型肝炎
Phase 1 safety and pharmacokinetics studies of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies
medRxiv

2021年07月23日

COVID-19